Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Baird Initiates Coverage On Climb Bio with Outperform Rating, Announces Price Target of $9

Author: Benzinga Newsdesk | August 15, 2025 09:18am

Baird analyst Colleen Kusy initiates coverage on Climb Bio (NASDAQ:CLYM) with a Outperform rating and announces Price Target of $9.

Posted In: CLYM